{
  "ticker": "NTI",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02966571",
  "id": "02966571",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250707",
  "time": "0932",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250707/pdf/06ljmzpygsqkww.pdf",
  "summary": "### Summary of ASX Announcement: Neurotech\u2019s Rett Syndrome Clinical Trial Results  \n\n- **Publication of Phase I/II Rett syndrome trial results** in *Journal of Paediatrics and Child Health*.  \n- **Key findings**:  \n  - NTI164 (0.08% THC cannabis extract) was well tolerated.  \n  - Clinical improvements observed in neurological, behavioural, and functional measures.  \n  - Supports potential as a therapy for Rett syndrome.  \n- **Next steps**: Reinforces regulatory advancement prospects for NTI164.  \n\n*No material trading or capital markets actions identified (e.g., capital raising, timetable updates). Focus is on clinical validation.*",
  "usage": {
    "prompt_tokens": 1167,
    "completion_tokens": 140,
    "total_tokens": 1307,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-06T23:45:27.879554"
}